Vazalore Patent Expiration

Vazalore is a drug owned by Plx Pharma Inc. It is protected by 7 US drug patents filed from 2014 to 2023. Out of these, 4 drug patents are active and 3 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 29, 2032. Details of Vazalore's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216150 pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Sep, 2032

(7 years from now)

Active
US10786444 PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Sep, 2032

(7 years from now)

Active
US10646431 PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Sep, 2032

(7 years from now)

Active
US9226892 pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Sep, 2032

(7 years from now)

Active
US9101637 Methods of treating inflammation with compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity
Mar, 2022

(2 years ago)

Expired
US8865187 Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity
Mar, 2022

(2 years ago)

Expired
US9351984 Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity
Dec, 2021

(2 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vazalore's patents.

Given below is the list of recent legal activities going on the following patents of Vazalore.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Yr, Small Entity 14 Mar, 2024 US10786444
Payment of Maintenance Fee, 4th Yr, Small Entity 25 Oct, 2023 US10646431
Expire Patent 18 Sep, 2023 US9101637
Payment of Maintenance Fee, 8th Yr, Small Entity 02 Aug, 2023 US9226892
7.5 yr surcharge - late pmt w/in 6 mo, Small Entity 02 Aug, 2023 US9226892
Payment of Maintenance Fee, 8th Yr, Small Entity 07 Jun, 2023 US9216150
Maintenance Fee Reminder Mailed 03 Apr, 2023 US9101637
Expire Patent 28 Nov, 2022 US8865187
Maintenance Fee Reminder Mailed 13 Jun, 2022 US8865187
Recordation of Patent Grant Mailed 29 Sep, 2020 US10786444


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Vazalore and ongoing litigations to help you estimate the early arrival of Vazalore generic.

Vazalore's Litigations

Vazalore been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 02, 2014, against patent number US8865187. The petitioner , challenged the validity of this patent, with Lenard M. Lichtenberger as the respondent. Click below to track the latest information on how companies are challenging Vazalore's patents.

Last updated on November 5, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8865187 January, 2014 Decision
(17 Jun, 2014)
Lenard M. Lichtenberger

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Vazalore is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vazalore's family patents as well as insights into ongoing legal events on those patents.

Vazalore's Family Patents

Vazalore has patent protection in a total of 18 countries. It's US patent count contributes only to 37.3% of its total global patent coverage. 8 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Vazalore.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Vazalore's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 29, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Vazalore Generics:

There are no approved generic versions for Vazalore as of now.

Alternative Brands for Vazalore

Vazalore which is used for targeting release to the small intestine, reducing fever, and relieving minor aches and pains., has several other brand drugs in the same treatment category and using the same active ingredient (Aspirin). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Bionpharma
Naproxen Sodium Used for reducing fever.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Aspirin. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Boehringer Ingelheim
Aggrenox
Bristol Myers Squibb
Pravigard Pac (copackaged)
Genus Lifesciences
Yosprala
Haleon Us Holdings
Excedrin (migraine Relief)






About Vazalore

Vazalore is a drug owned by Plx Pharma Inc. It is used for targeting release to the small intestine, reducing fever, and relieving minor aches and pains. Vazalore uses Aspirin as an active ingredient. Vazalore was launched by Plx Pharma in 2021.

Approval Date:

Vazalore was approved by FDA for market use on 26 February, 2021.

Active Ingredient:

Vazalore uses Aspirin as the active ingredient. Check out other Drugs and Companies using Aspirin ingredient

Treatment:

Vazalore is used for targeting release to the small intestine, reducing fever, and relieving minor aches and pains.

Dosage:

Vazalore is available in capsule form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
325MG CAPSULE Over the counter ORAL
81MG CAPSULE Over the counter ORAL